CFRX - ContraFect Corp Stock Price, Fair Value and News
0.03USD0.00 (0.00%)Market Closed
Market Summary
USD0.030.00
Market Closed0.00%
CFRX Stock Price
View Fullscreen
CFRX RSI Chart
CFRX Valuation
CFRX Price/Sales (Trailing)
CFRX Profitability
CFRX Fundamentals
CFRX Earnings
Breaking Down CFRX Revenue
Last 90 days
-88.5%
Trailing 12 Months
-60%
How does CFRX drawdown profile look like?
CFRX Financial Health
CFRX Investor Care
Tracking the Latest Insider Buys and Sells of ContraFect Corp
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Dec 13, 2019 | sucoff cary | bought | 19,500 | 0.39 | 50,000 | - |
| Dec 13, 2019 | messinger michael | bought | 1,850 | 0.37 | 5,000 | chief financial officer |
| Dec 13, 2019 | low david n. | bought | 129,000 | 0.43 | 300,000 | - |
Which funds bought or sold CFRX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
| Mar 11, 2024 | VANGUARD GROUP INC | sold off | -100 | -9,298 | - | -% |
| Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -14,000 | - | -% |
| Feb 14, 2024 | GROUP ONE TRADING, L.P. | sold off | -100 | -1.00 | - | -% |
| Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -3.00 | - | -% |
| Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -12,003 | - | -% |
| Feb 14, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
| Feb 13, 2024 | MORGAN STANLEY | sold off | -100 | -68.00 | - | -% |
| Feb 13, 2024 | ACADIAN ASSET MANAGEMENT LLC | unchanged | - | -10,000 | - | -% |
| Feb 13, 2024 | FMR LLC | sold off | -100 | -1.00 | - | -% |
Are Funds Buying or Selling CFRX?
Calls
Puts
Net Call Options
No. of Funds
Unveiling ContraFect Corp's Major ShareHolders
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2024 | armistice capital, llc | 9.99% | 1,395,093 | SC 13G/A | |
| Feb 14, 2023 | armistice capital, llc | 9.99% | 4,828,644 | SC 13G | |
| Sep 09, 2022 | federated hermes, inc. | 4.11% | 1,685,391 | SC 13G/A | |
| Jul 19, 2022 | biotechnology value fund l p | 2.4% | 963,170 | SC 13G/A | |
| Feb 14, 2022 | federated hermes, inc. | 18.55% | 7,297,188 | SC 13G/A | |
| Feb 14, 2022 | pfizer inc | 4.54% | 1,785,267 | SC 13G/A | |
| Apr 15, 2021 | biotechnology value fund l p | 5.1% | 2,017,290 | SC 13G/A | |
| Apr 12, 2021 | blackrock inc. | 4.1% | 1,614,857 | SC 13G/A | |
| Feb 16, 2021 | altium capital management lp | 4.99% | 1,500,000 | SC 13G/A | |
| Feb 16, 2021 | cvi investments, inc. | - | 1,460,607 | SC 13G/A |
Recent SEC filings of ContraFect Corp
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Feb 14, 2024 | SC 13G/A | Major Ownership Report |
Peers (Alternatives to ContraFect Corp)
| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MRNA | 48.1B | 6.8B | 21.21% | -3.50% | -8.06 | 7.03 | -64.45% | -224.75% |
HILS | 22.4B | 152.6K | -0.77% | 465779.94% | -2.4K | 146.8K | - | -9.98% |
ALNY | 19.0B | 2.0B | -0.48% | -24.66% | -57.25 | 9.49 | 75.20% | 68.82% |
BMRN | 15.9B | 2.5B | -3.50% | -10.49% | 77.41 | 6.43 | 13.74% | 186.89% |
INCY | 11.9B | 3.8B | -4.91% | -21.97% | 15.99 | 3.16 | 8.58% | 129.81% |
| MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -14.74% | -44.14% | -10.83 | 14.44 | 425.83% | 18.94% |
BBIO | 5.2B | 107.9M | -3.68% | 92.64% | -9.5 | 48.09 | 54.84% | -28.31% |
AXSM | 3.5B | 270.6M | -0.50% | 3.10% | -14.69 | 12.99 | 440.80% | -27.84% |
ARWR | 3.0B | 240.7M | -7.87% | -39.98% | -10.07 | 12.18 | -1.03% | -92.09% |
ACAD | 2.8B | 726.4M | -5.69% | -19.43% | -45.92 | 3.87 | 40.45% | 71.62% |
| SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | -1.57% | -9.52% | 24.79 | 4.45 | 85.90% | -14.05% |
NVAX | 659.2M | 983.7M | 3.97% | -34.13% | -1.21 | 0.67 | -50.36% | 17.16% |
CRBP | 400.8M | 881.7K | 1.98% | 349.41% | -8.99 | 466.16 | -77.61% | -5.33% |
INO | 280.7M | 4.9M | -3.22% | 25.10% | -2.08 | 57.68 | -54.97% | 51.71% |
IBIO | 7.0M | 2.1M | -29.72% | 84.40% | -0.26 | 2.14 | -13.45% | 66.37% |
ContraFect Corp News
Latest updates
ContraFect Corp Earnings Report: Key Takeaways & Analysis
Balance Sheet
(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -52.6% | 9.00 | 19.00 | 21.00 | 21.00 | 23.00 | 41.00 | 56.00 | 67.00 | 78.00 | 87.00 | 97.00 | 51.00 | 60.00 | 68.00 | 26.00 | 35.00 | 17.00 | 21.00 | 30.00 | 33.00 | 41.00 |
| Current Assets | -60.5% | 7.00 | 17.00 | 18.00 | 18.00 | 20.00 | 38.00 | 52.00 | 63.00 | 74.00 | 76.00 | 91.00 | 47.00 | 56.00 | 45.00 | 22.00 | 31.00 | 13.00 | 16.00 | 25.00 | 31.00 | 39.00 |
| Cash Equivalents | -62.5% | 5.00 | 14.00 | 12.00 | 9.00 | 5.00 | 10.00 | 10.00 | 17.00 | 20.00 | 21.00 | 65.00 | 15.00 | 18.00 | 31.00 | 11.00 | 24.00 | 11.00 | 7.00 | 7.00 | 8.00 | 11.00 |
| Net PPE | -8.1% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Liabilities | -26.9% | 15.00 | 20.00 | 24.00 | 33.00 | 26.00 | 28.00 | 26.00 | 17.00 | 25.00 | 29.00 | 35.00 | 38.00 | 42.00 | 53.00 | 18.00 | 19.00 | 13.00 | 12.00 | 12.00 | 27.00 | 42.00 |
| Current Liabilities | -25.2% | 12.00 | 16.00 | 20.00 | 21.00 | 24.00 | 21.00 | 17.00 | 12.00 | 10.00 | 8.00 | 8.00 | 6.00 | 5.00 | 6.00 | 9.00 | 10.00 | 8.00 | 4.00 | 6.00 | 6.00 | 5.00 |
| Shareholder's Equity | - | - | - | - | - | - | 13.00 | 30.00 | 49.00 | 53.00 | 57.00 | 62.00 | 13.00 | 18.00 | 14.00 | 9.00 | 16.00 | 4.00 | 9.00 | 17.00 | 6.00 | - |
| Retained Earnings | -1.6% | -340 | -334 | -327 | -325 | -315 | -298 | -280 | -260 | -256 | -250 | -245 | -240 | -233 | -237 | -219 | -212 | -201 | -196 | -187 | -199 | -205 |
| Additional Paid-In Capital | 0.2% | 334 | 334 | 324 | 314 | 313 | 312 | 311 | 310 | 309 | 308 | 307 | 253 | 252 | 252 | 228 | 228 | 206 | 206 | 205 | 205 | 205 |
| Shares Outstanding | 0% | 11.00 | 11.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Float | - | - | - | - | - | - | 121 | - | - | - | 173 | - | - | - | 177 | - | - | - | 40.00 | - | - | - |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -6.2% | -8,651 | -8,149 | -8,800 | -9,994 | -9,654 | -14,585 | -11,767 | -8,568 | -11,053 | -12,445 | -9,059 | -7,515 | -7,978 | -10,145 | -7,549 | -7,638 | -3,675 | -8,789 | -7,324 | -7,056 | -6,000 |
| Share Based Compensation | -10.8% | 709 | 795 | 932 | 983 | 1,006 | 965 | 919 | 811 | 864 | 938 | 581 | 639 | 652 | 652 | 633 | 361 | 392 | 370 | 324 | 319 | 383 |
| Cashflow From Investing | -100.0% | - | 1,985 | 2,745 | 8,067 | 4,769 | 14,497 | 4,750 | 4,997 | 9,872 | -31,395 | 4,913 | 4,848 | -4,718 | -21,531 | -6,003 | -126* | 6,800 | 9,341 | 5,830 | 4,422 | 1,959 |
| Cashflow From Financing | -103.9% | -340 | 8,722 | 9,012 | - | - | - | - | - | - | - | 53,907 | - | 29.00 | 51,863 | - | - | - | - | - | - | 10,427 |
CFRX Income Statement
2023-09-30Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Operating expenses: | ||||
| Research and development | $ 3,869 | $ 10,814 | $ 14,034 | $ 40,299 |
| General and administrative | 2,808 | 3,366 | 9,476 | 9,886 |
| Restructuring | 7,719 | 7,719 | ||
| Total operating expenses | 6,677 | 21,899 | 23,510 | 57,904 |
| Loss from operations | (6,677) | (21,899) | (23,510) | (57,904) |
| Other income (expense): | ||||
| Interest income, net | 109 | 9 | 310 | 64 |
| Other expense | (96) | |||
| Change in fair value of warrant liabilities | 1,209 | 4,823 | 8,998 | 2,527 |
| Total other income | 1,318 | 4,832 | 9,212 | 2,591 |
| Net loss | $ (5,359) | $ (17,067) | $ (14,298) | $ (55,313) |
| Per share information: | ||||
| Basic net loss per share | $ (0.5) | $ (34.72) | $ (2.57) | $ (112.51) |
| Weighted average shares outstanding basic | 10,704,803 | 491,626 | 5,559,348 | 491,626 |
| Diluted net loss per share | $ (0.5) | $ (34.72) | $ (2.57) | $ (112.51) |
| Weighted Average Number of Shares Outstanding, Diluted | 10,704,803 | 491,626 | 5,559,348 | 491,626 |
CFRX Balance Sheet
2023-09-30Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 5,413 | $ 8,907 |
| Marketable securities | 4,775 | |
| Prepaid expenses | 1,095 | 1,382 |
| Other current assets | 12 | 2,642 |
| Total current assets | 6,520 | 17,706 |
| Property and equipment, net | 511 | 627 |
| Operating lease right-of-use assets | 1,989 | 2,241 |
| Other assets | 105 | 105 |
| Total assets | 9,125 | 20,679 |
| Current liabilities: | ||
| Accounts payable | 8,179 | 13,671 |
| Accrued and other current liabilities | 3,464 | 6,498 |
| Current portion of lease liabilities | 680 | 671 |
| Total current liabilities | 12,323 | 20,840 |
| Warrant liabilities | 652 | 9,299 |
| Long-term portion of lease liabilities | 1,873 | 2,210 |
| Other liabilities | 38 | 182 |
| Total liabilities | 14,886 | 32,531 |
| Commitments and contingencies | ||
| Stockholders' deficit: | ||
| Preferred stock, $0.0001 par value, 25,000,000 shares authorized and none issued and outstanding at September 30, 2023 and December 31, 2022 | ||
| Common stock, $0.0001 par value, 125,000,000 shares authorized, 10,704,803 and 594,983 shares outstanding at September 30, 2023 and December 31, 2022 | 1 | 1 |
| Additional paid-in capital | 334,243 | 313,884 |
| Accumulated other comprehensive loss | (32) | |
| Accumulated deficit | (340,003) | (325,705) |
| Total stockholders' deficit | (5,759) | (11,852) |
| Total liabilities and stockholders' deficit | $ 9,125 | $ 20,679 |
| CEO | Dr. Roger James Pomerantz F.A.C.P., FACP, M.D. |
|---|---|
| WEBSITE | contrafect.com |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 23 |